

Lampiran 1 Strategi Pencarian

Basis data	Kata kunci	Jumlah
PubMed (MEDLINE dan PMC)	("malaria"[MeSH Terms] OR "malaria"[All Fields] OR "malarías"[All Fields] OR "malaria's"[All Fields] OR "malariae"[All Fields]) AND ("vaccin"[Supplementary Concept] OR "vaccin"[All Fields] OR "vaccination"[MeSH Terms] OR "vaccination"[All Fields] OR "vaccinable"[All Fields] OR "vaccinal"[All Fields] OR "vaccinate"[All Fields] OR "vaccinated"[All Fields] OR "vaccinates"[All Fields] OR "vaccinating"[All Fields] OR "vaccinations"[All Fields] OR "vaccination s"[All Fields] OR "vaccinator"[All Fields] OR "vaccinators"[All Fields] OR "vaccine s"[All Fields] OR "vaccined"[All Fields] OR "vaccines"[MeSH Terms] OR "vaccines"[All Fields] OR "vaccine"[All Fields] OR "vaccins"[All Fields]) <i>Filters: Randomized Controlled Trial</i>	376
Cochrane Library	((MeSH descriptor: [Malaria] explode all trees) OR (malaria*)) AND (MeSH descriptor: [Vaccines] in all MeSH products) OR (vaccin*) OR (MeSH descriptor: [Malaria Vaccines] explode all trees) AND random* <i>Filters: Trial</i>	666
Science Direct	Malaria AND Vaccine AND Random -review	4194
Google Scholar	Malaria AND Vaccine AND Random -review	17400

a

Comparative Efficacy, Safety, and Immunogenicity of Malarial Vaccines: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

To enable PROSPERO to focus on COVID-19 submissions, this registration record has undergone basic automated checks for eligibility and is published exactly as submitted. PROSPERO has never provided peer review, and usual checking by the PROSPERO team does not endorse content. Therefore, automatically published records should be treated as any other PROSPERO registration. Further detail is provided [here](#).

Review methods were amended after registration. Please see the revision notes and previous versions for detail.

Citation

Fitrandi Taslim, Bagus Hermansyah, Dini Agustina, Vania Rahmantria. Comparative Efficacy, Safety, and Immunogenicity of Malarial Vaccines: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PROSPERO 2024 CRD42024528994 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024528994

Review question

1. How do the efficacies of different malarial vaccines in preventing clinical malaria, severe malaria, and hospitalization?
2. How do the different malarial vaccines compare in terms of their ability to induce antibody and/or cellular immune responses?
3. Is there a significant difference in the incidence and severity of adverse events reported for different malarial vaccines?

Searches [1 change]

The systematic review will be conducted using an exhaustive search of literature from various databases. The sources that will be searched include PubMed, ScienceDirect, Cochrane Library, and Google Scholar. These databases have been chosen for their extensive collection of academic and scientific articles, which will provide a comprehensive view of the existing literature on malarial vaccines.

The search will not be limited by date and will cover literature from the inception of each database up until the most recent publications available at the time of the search. This approach ensures that the review is as comprehensive and up-to-date as possible.

In terms of language restrictions and resource constraints, the search for unpublished studies or grey literature will be conducted exclusively through Google Scholar. While this may not capture all unpublished studies, Google Scholar indexes a wide range of literature and will provide a broad overview of both published and unpublished works relevant to malarial vaccines.

Types of study to be included

Only Randomized Controlled Trials (RCTs) which are conducted on humans will be included in this systematic review. Studies of other designs will be excluded

Condition or domain being studied

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female *Anopheles* mosquitoes. It is prevalent in tropical and subtropical regions, including parts of sub-Saharan Africa, Asia, and the Americas. The disease is characterized by high fever, flu-like symptoms, and other complications that can lead to death if not treated promptly. The domain being studied here is the development and effectiveness of malarial vaccines. This includes studying the safety, efficacy, and potential impacts of these vaccines on health and wellbeing outcomes, with the ultimate goal of reducing the global burden of malaria.

Participants/population

The population of interest for this review includes individuals of all age groups, from infants to older adults. We will not limit our review to healthy individuals; instead, we aim to include studies involving diverse populations, including those with pre-existing health conditions, those exposed to malaria, and those living in regions with varying levels of malaria transmission. This broad inclusion criteria will allow us to capture a comprehensive view of the safety and efficacy of malaria vaccines across different population subgroups.

Intervention(s), exposure(s)

All currently available malarial vaccine and any other vaccines that have received regulatory approval or are in the stages of clinical trials.

Comparator(s)/control

The comparators will include any type of control group, which may consist of placebo, standard care, alternative drug treatments, or different malarial vaccines. The inclusion criteria are not restricted to a specific type of control, allowing for comprehensive comparison across various control conditions used in the randomized controlled trials.

Context

The systematic review focuses on the context of malaria, a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female *Anopheles* mosquitoes.

Main outcome(s)

Efficacy-related outcomes:

1. Incidence of clinical malaria, defined as the number of new cases of malaria that develop in a population at risk during a specified time period.
2. Hospital admission for malaria, defined as the number of participants who are admitted to a hospital with a primary diagnosis of malaria.
3. Severe malarial anemia, defined as a case of malaria that is accompanied by a very low number of red blood cells.
4. Malaria-specific mortality, defined as death where malaria is recorded as the primary cause on the death certificate.
5. Participants with sterile protection, defined as participants who show no evidence of malaria infection after receiving the malaria intervention.
6. Parasitemia measurement, defined as the quantification of malaria parasites in the blood.

Additional outcome(s)

Safety-related outcomes:

1. Immediate reactogenicity, refers to reactions that occur soon after vaccination.

2. Local and systemic adverse events refer to side effects that occur at the site of the intervention or involve the whole body.

3. Serious adverse events, refers to adverse events that result in significant disability or hospitalization, are life-threatening, or result in death.

Immunogenicity refers to the ability of the vaccine to provoke an immune response in the participants. Measured by assessing the presence and levels of antibodies.

Data extraction (selection and coding)

Study Selection:

Two independent reviewers will apply the eligibility criteria and select studies for inclusion in the systematic review. Each reviewer will independently screen the titles and abstracts of identified records and select potentially relevant studies. Full texts of these potentially relevant studies will then be retrieved and independently assessed for eligibility by both reviewers. The reviewers will be blinded to each other's decision during this process.

Any disagreements between the reviewers during the study selection process will be resolved through discussion until consensus is reached. If consensus cannot be reached, a third reviewer will be consulted.

We will use Rayyan, a web-based reference management software, to record the decisions at each stage of the study selection process. This will ensure a transparent and reproducible study selection process.

Data Extraction:

Two independent reviewers will extract data from the included studies. The extracted data will include information about study design and methodology, participant demographics and baseline characteristics, and numbers of events or measures of effect.

The reviewers will independently extract the data. Any disagreements between the reviewers during the data extraction process will be resolved through discussion until consensus is reached. If consensus cannot be reached, a third reviewer will be consulted.

In the case of the missing data, we will attempt to contact the original investigators to obtain the necessary details. If the missing data cannot be obtained, we will address this in the data synthesis and discuss the potential impact on our review findings.

We will use the Systematic Review Data Repository-Plus (SRDR+) for data extraction and management. This web-based tool allows for efficient extraction, storage, and sharing of systematic review data. All extracted data will be made publicly available on the SRDR+ platform upon completion of the review.

Risk of bias (quality) assessment

The risk of bias will be assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, which evaluates five domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result.

The assessment will be done at both the study and outcome level. The results of the risk of bias assessment will inform data synthesis, with high-risk studies potentially being given less weight.

Two independent reviewers will be involved in the quality assessment, and any disagreements between reviewers will be resolved through discussion or consultation with a third reviewer. This rigorous approach will ensure the reliability and validity of our review findings.

Strategy for data synthesis

We will synthesize the data from the included studies if they are sufficiently homogenous in terms of design, population, intervention, and outcomes. A minimum of two studies will be required for data synthesis.

The data to be synthesized will include the primary and secondary outcomes identified in the protocol. Summary effect measures such as risk ratios, odds ratios, or mean differences will be used as appropriate.

We will use a random-effects meta-analysis to combine individual study data, given the likely clinical and methodological diversity among the included studies. This approach assumes that the true effect size varies from study to study and provides a more conservative estimate of the effect size and its confidence interval.

If there is sufficient data and it is deemed appropriate, we may also conduct a network meta-analysis. This would allow us to compare multiple interventions simultaneously and could provide additional insights into the relative effectiveness of different malaria vaccines.

In the case of substantial clinical or methodological heterogeneity, or if quantitative synthesis is not appropriate, we will conduct a narrative synthesis of the findings.

All analysis will be conducted using appropriate statistical software. Sensitivity analyses will be conducted to assess the robustness of the review findings.

Analysis of subgroups or subsets

In our systematic review, we plan to conduct a thorough investigation of various subgroups. These subgroups are defined based on intervention types and participant characteristics.

The rationale for this investigation is to understand the differential effects of malarial vaccines across diverse populations and study conditions. We anticipate that the efficacy, safety, and immunogenicity of the vaccines may vary based on these factors.

Our planned analytic approach may include meta-regression and tests of interaction to evaluate the differences among the subgroups. The results of this subgroup analysis will provide valuable insights into the factors that influence the effectiveness of malarial vaccines.

Contact details for further information

Fitrandi Kusiyanto Taslim
fitrandataslim@outlook.com

Organisational affiliation of the review

Jember University
<https://uncj.ac.id/>

Review team members and their organisational affiliations

Mr Fitrandi Taslim. Medical Faculty of Jember University
Mrs Bagus Hermansyah. Medical Faculty of Jember University
Mrs Dini Agustina. Medical Faculty of Jember University
Miss Vania Rahmantia. Medical Faculty of Jember University

Type and method of review

Meta-analysis, Network meta-analysis, Systematic review

Anticipated or actual start date

01 May 2024

Anticipated completion date [3 changes]

30 September 2024

Funding sources/sponsors

None

Grant number(s)

State the funder, grant or award number and the date of award

None

Conflicts of interest

None

None known

Language

English, Indonesian

Country

Indonesia

Stage of review

Review Ongoing

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

MeSH headings have not been applied to this record

Date of registration in PROSPERO

05 May 2024

Date of first submission

24 April 2024

Details of any existing review of the same topic by the same authors

None

Stage of review at time of this submission [3 changes]

Stage	Started	Complete
Preliminary searches	Yes	Yes
Piloting of the study selection process	Yes	Yes
Formal screening of search results against eligibility criteria	Yes	Yes
Data extraction	Yes	Yes
Risk of bias (quality) assessment	Yes	Yes
Data analysis	Yes	Yes

Revision note

Updated the expected date of completion and the stages.

The record owner confirms that the information they have supplied for this submission is accurate and complete and they understand that deliberate provision of inaccurate information or omission of data may be construed as scientific misconduct.

The record owner confirms that they will update the status of the review when it is completed and will add publication details in due course.

Versions

05 May 2024

05 May 2024

23 June 2024

23 July 2024

19 August 2024

Lampiran 3 Tabel karakteristik studi

ID Studi	Negara	Grup	Intervensi	Subjek	Umur	Ukuran Umur	Laki-laki (N)	Laki-laki (%)	Lama Studi
(Abdulla et al., 2008)	Tanzania		Hepatitis B	170	7.9 ± 0.8	mean ± SD, minggu	85	50.00%	19 bulan
			RTS,S/AS02D	170	7.8 ± 0.8		91	53.53%	
(Acosta et al., 1999)	Tanzania		SPf66	550	52.3 ± 27.7	mean ± SD, minggu	252	45.82%	30 bulan
			Placebo	541	53.0 ± 28.2		259	47.87%	
(Agnandji et al., 2010)	Ghana, Tanzania, Gabon		RTS,S/AS01E (012)	170	7 ± 1	mean ± SD, minggu	51%	51.00%	8 bulan
			RTS,S/AS01E (017)	170	7 ± 1		51%	51.00%	
			Control	171	7 ± 1		51%	51.00%	
(Alonso et al., 1994)	Tanzania		SPf66	274	3.4 ± 1.5	mean ± SD, tahun	145	52.92%	17 bulan
			Placebo	312	3.5 ± 1.5		154	49.36%	
(Alonso et al., 2004)	Mozambique	Kohort 1 (Manhiça)	Control	802	35.9 ± 13.4	mean ± SD, bulan	N/A	N/A	21 bulan
			RTS,S/AS02A	803	35.6 ± 14		N/A	N/A	
		Kohort 2 (Ilha Josina)	Control	208	34.9 ± 13.1		N/A	N/A	
			RTS,S/AS02A	209	35.9 ± 13		N/A	N/A	
(Aponte et al., 2007)	Mozambique		Engerix-B	92	8.3 ± 1	mean ± SD, minggu	39	42.39%	21 bulan
			RTS,S/AS02D	93	8.3 ± 1.4		50	53.76%	
(Arévalo-Herrera et al., 2022)	Colombia	Fase IIa (Naive Group)	PvCS LSP	11	20-43	min-max, tahun	4	36.36%	10 bulan
			Saline (Placebo)	6	21-42		3	50.00%	
		Fase IIb (Semi-Immune Group)	PvCS LSP	12	20-44		6	50.00%	
			Saline (Placebo)	6	19-28		2	33.33%	
(Asante et al., 2020)	Ghana		RTS,S coad	231	6.3 ± 0.3	mean ± SD, bulan	115	49.78%	10 bulan
			RTS,S alone	236	6.3 ± 0.3		117	49.58%	
			Control	232	6.3 ± 0.3		119	51.29%	
(Bejon et al., 2008b)	Kenya, Tanzania		RTS,S/AS01E	447	11.4	mean, bulan	230	51.45%	8 bulan
			Rabies	447	11.3		222	49.66%	
(Bélard et al., 2011)	Gabon		Rabies	10	3.5 (1.9-48)	mean (min-max), tahun	5	50.00%	13 bulan
			GMZ2-30	10	3.5 (2.2-5.6)		5	50.00%	
			GMZ2-100	10	3.5 (2.2-5.6)		5	50.00%	
(Bojang et al., 1998)	Gambia		SPf66	269	27.4 ± 1.7	mean ± SD, bulan	139	51.67%	18 bulan
			IPV	204	27.3 ± 1.8		122	59.80%	
(Bojang et al., 2001)	Gambia		RTS,S/AS02	131	25 (20-35)	median (IQR), tahun	131	100.00%	22 bulan
			Control	119	25 (19-38)		119	100.00%	
(Bojang et al., 2005)	Gambia	Fase 1 (6-11 tahun)	Rabies	30	8	mean, tahun	54.40%	54.40%	10 bulan
			RTS,S/AS02A 10µg	20	8		54.40%	54.40%	
			RTS,S/AS02A 25µg	20	8		54.40%	54.40%	
			RTS,S/AS02A 50µg	20	8		54.40%	54.40%	
		Fase 2 (1-5 tahun)	Rabies	45	2.8		48.90%	48.90%	
			RTS,S/AS02A 10µg	30	2.8		48.90%	48.90%	
			RTS,S/AS02A 25µg	30	2.8		48.90%	48.90%	

			RTS,S/AS02A 50µg	30	2.8		48.90%	48.90%	
(Bougouma et al., 2022)	Burkina Faso	Kohort 1 (25-60 bulan)	BK-SE36 SC	18	43.7 ± 11.3	mean ± SD, bulan	7	38.89%	19 bulan
			BK-SE36 IM	18	46.1 ± 9.6		7	38.89%	
			Control (Synflorix)	18	47.8 ± 9		6	33.33%	
		Kohort 2 (12-24 bulan)	BK-SE36 SC	18	18.5 ± 3.7		8	44.44%	
			BK-SE36 IM	18	18.2 ± 3.1		6	33.33%	
			Control (Synflorix)	18	19.3 ± 3		8	44.44%	
(Chitnis et al., 2015)	India		JAIVAC 10	10	26.8 (1.43)	mean (SEM), tahun	10	100.00%	15 bulan
			JAIVAC 25	10	28.94 (1.99)		10	100.00%	
			JAIVAC 50	10	27.8 (2.18)		10	100.00%	
			Hepatitis B	15	26.72 (1.15)		15	100.00%	
(Coulibaly et al., 2022)	Mali		PfSPZ-CVac	31	31.5 ± 8.9	mean ± SD, tahun	20	64.52%	14 bulan
			Control	31	29.3 ± 8		26	83.87%	
(Creech et al., 2013)	United States		Ad35.CS.01 108	14	28	mean, tahun	50%	50.00%	7 bulan
			Ad35.CS.01 109	15	28		50%	50.00%	
			Ad35.CS.01 1010	15	28		50%	50.00%	
			Ad35.CS.01 1011	16	28		50%	50.00%	
			Placebo	12	28		50%	50.00%	
(Cummings et al., 2024)	United States		RTS,S + FMP1-separate	15	30.9 ± 7	mean ± SD, tahun	11	73.33%	11 bulan
			RTS,S + FMP1-same	15	26.3 ± 5		10	66.67%	
			FMP1-alone	15	29.9 ± 7		8	53.33%	
			RTS,S-alone	15	31.4 ± 6		8	53.33%	
			Control	11	29.4 ± 8		6	54.55%	
(Dattoo et al., 2024)	Burkina Faso, Mali, Kenya, Tanzania		R21/Matrix-M	3103	19.1 ± 9	mean ± SD, bulan	1607	51.79%	18 bulan
			Control	1541	18.9 ± 9		805	52.24%	
(Ezoe et al., 2020)	Japan	Dosis separuh	BK-SE36/CpG	7	23.1 ± 5.4	mean ± SD, tahun	7	100.00%	24 bulan
			Placebo	3	24 ± 4.4		3	100.00%	
		Dosis penuh	BK-SE36/CpG	11	27.4 ± 5.3		11	100.00%	
			Placebo	5	28 ± 3.9		5	100.00%	
(Laurens et al., 2013)	Mali		FMP2.1/AS02A	199	3.4 ± 1.5	mean ± SD, tahun	46%	46.00%	24 bulan
			Control	201	3.4 ± 1.5		46%	46.00%	
(Lell et al., 2009)	Gabon		RTS,S/AS01E	90	39.6 ± 11.5	mean ± SD, bulan	54	60.00%	16 bulan
			RTS,S/AS02D	90	39.3 ± 11.2		38	42.22%	
(Leroux-Roels et al., 2014)	Belgium		RTS,S/AS01	11	20.9 ± 2.3	mean ± SD, tahun	33.40%	33.40%	4 bulan
			RTS,S/AS02	11	20.7 ± 2.9		33.40%	33.40%	
			RTS,S/Saline	12	21.6 ± 2.3		25%	25.00%	
			MSP3 15	15	1.4 (1-2)		50%	50.00%	
(Lusingu et al., 2009)	Tanzania		MSP 30	15	1.4 (1-2)	mean (min-max), tahun	50%	50.00%	12 bulan
			Hepatitis B	15	1.4 (1-2)		50%	50.00%	
			Engerix-B	30	2.5 ± 1.04		10	33.33%	
(Macete et al., 2007)	Mozambique		RTS,S/AS02A	30	2.6 ± 1.17	mean ± SD, tahun	16	53.33%	16 bulan
			Control	20	21-43		N/A	N/A	
(Malkin et al., 2008)	China		PfCP-2.9 5	20	21-43	min-max, tahun	N/A	N/A	12 bulan
							N/A	N/A	

			PfCP-2.9 20	10	21-43		N/A	N/A	
			PfCP-2.9 50	10	21-43		N/A	N/A	
(Moorthy et al., 2004)	Gambia		ME-TRAP	141	20 (17-32)	median (IQR), tahun	141	100.00%	6 bulan
			Rabies	155	21 (18-30)		155	100.00%	
(Mordmüller et al., 2010)	Gabon		GMZ2	20	26.8 (18-42.6)	mean (min-max), tahun	20	100.00%	13 bulan
			Rabies	20	25.8 (18.3-44.2)		20	100.00%	
(Ogutu et al., 2009)	Kenya		FMP1/AS02	200	29.6 ± 10.1	mean ± SD, bulan	101	50.50%	10 bulan
			RabipurH	200	30 ± 9.9		118	59.00%	
(Otieno et al., 2016)	Kenya		RTS,S/AS01	99	10 ± 5	mean ± SD, bulan	42	42.42%	34 bulan
			Rabies	101	9.5 ± 4.6		56	55.45%	
		Kohort 1 (21-45 tahun)	BK-SE36/CpG	30	36.5 ± 5.3		50%	50.00%	
			Rabies	15	38.3 ± 6.9		60%	60.00%	
(Ouédraogo et al., 2023)	Burkina Faso	Kohort 2 (5-10 tahun)	BK-SE36/CpG	30	7.4 ± 1.1	mean ± SD, tahun	50%	50.00%	
			Rabies	15	8.1 ± 1.3		53%	53.00%	
		Kohort 3 (12-24 bulan)	BK-SE36/CpG	31	1.6 ± 0.2		61%	61.00%	
			Rabies	14	1.6 ± 0.2		43%	43.00%	
		012 bulan	RTS,S/AS02D	45	11.2 ± 3.3		49%	49.00%	
(Owusu-Agyei et al., 2009)	Ghana		RTS,S/AS01E	90	10.9 ± 3.7	mean ± SD, bulan	56%	56.00%	19 bulan
			Rabies	45	10.9 ± 3.5		40%	40.00%	
		017 bulan	RTS,S/AS02D	90	10.4 ± 3.6		51%	51.00%	
			RTS,S/AS01E	90	10.7 ± 3.3		47%	47.00%	
			RTS,S/AS01B	85	24.9 (17-35)		64	75.29%	
(Polhemus et al., 2009)	Kenya		RTS,S/AS02A	85	25.2 (18-35)	mean (min-max), tahun	66	77.65%	12 bulan
			Rabies	85	26.1 (18-35)		73	85.88%	
(RTS,S 2011)	Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Tanzania		RTS,S/AS01	3997	10.9 ± 3.8	mean ± SD, bulan	1965	49.16%	18 bulan
			Rabies	2003	10.9 ± 3.7		980	48.93%	
(RTS,S 2012)	Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Tanzania		RTS,S/AS01	4358	7.1 ± 1.4	mean ± SD, minggu	2236	51.31%	32 bulan
			MenC vaccine	2179	7.1 ± 1.4		1081	49.61%	
			PfAMA1 Alum 10	10	22.4 ± 3.1		10	100.00%	
			PfAMA1 Alum 50	10	22.6 ± 2		10	100.00%	
(Roestenberg et al., 2008)	Netherlands		PfAMA1 Mon 10	10	22.5 ± 4.5	mean ± SD, tahun	10	100.00%	14 bulan
			PfAMA1 Mon 50	9	22.6 ± 3.8		9	100.00%	
			PfAMA1 AS02 10	9	24.1 ± 7.3		9	100.00%	
			PfAMA1 AS02 50	8	24.4 ± 6.1		8	100.00%	
			EBA 5	18	26.7 ± 4.7		12	66.67%	
(El Sahly et al., 2010)	United States		EBA 20	18	24.8 ± 2.2	mean ± SD, tahun	7	38.89%	7 bulan
			EBA 80	18	28.1 ± 5.3		10	55.56%	
			EBA 160	18	25.2 ± 1.7		7	38.89%	
			Placebo	8	29.5 ± 5.3		5	62.50%	
(Sirima et al., 2007)	Burkina Faso		MSP3-LSP	15	27.1 ± 7.6	mean ± SD, tahun	15	100.00%	12 bulan
			Tetanus	15	26.7 ± 6.2		15	100.00%	

(Sirima et al., 2009)	Burkina Faso		MSP3 15	15	18.8 ± 3.6	mean ± SD, bulan	N/A	N/A	12 bulan
			MSP3 30	15	17.4 ± 3.2		N/A	N/A	
			Engerix B	15	18 ± 3.4		N/A	N/A	
(Sirima et al., 2022)	Burkina Faso	Kohort A	PfSPZ 4.5	8	35.1 ± 2.7	mean ± SD, tahun	2	25.00%	17 bulan
			PfSPZ 9	8	29.6 ± 4.9		7	87.50%	
			PfSPZ 1.8	8	31.1 ± 4.8		4	50.00%	
			PfSPZ 2.7A	8	28.6 ± 5.2		5	62.50%	
		Kohort B	PfSPZ 2.7B	39	30.7 ± 5.4		21	53.85%	
			Placebo	41	30.3 ± 5.5		23	56.10%	
(Sissoko et al., 2017b)	Mali		PfSPZ	46	24 ± 5	mean ± SD, tahun	38	82.61%	7 bulan
			Placebo	47	24 ± 5		6	12.77%	
(Sissoko et al., 2022)	Mali		1x8 PfSPZ	60	32.12 ± 8.85	mean ± SD, tahun	45	75.00%	13 bulan
			Placebo (NS)	60	32.27 ± 9.56		38	63.33%	
(Steinhardt et al., 2020)	Kenya	Grup 1 (5-9 tahun)	PfSPZ 4.5	8	05-Sep	min-max, tahun	N/A	N/A	8 bulan
			PfSPZ 9	8	05-Sep		N/A	N/A	
			PfSPZ 18	8	05-Sep		N/A	N/A	
			Placebo	12	05-Sep		N/A	N/A	
		Grup 2 (13-59 bulan)	PfSPZ 1.35	10	13-59	min-max, bulan	N/A	N/A	
			PfSPZ 2.7	9	13-59		N/A	N/A	
			PfSPZ 4.5	8	13-59		N/A	N/A	
			PfSPZ 9	9	13-59		N/A	N/A	
		Grup 3 (5-12 bulan)	PfSPZ 18	8	13-59	min-max, bulan	N/A	N/A	
			Placebo	20	13-59		N/A	N/A	
			PfSPZ 1.35	8	05-Dec		N/A	N/A	
			PfSPZ 2.7	10	05-Dec		N/A	N/A	
		Grup 3 (5-12 bulan)	PfSPZ 4.5	8	05-Dec	min-max, bulan	N/A	N/A	
			PfSPZ 9	10	05-Dec		N/A	N/A	
			PfSPZ 18	8	05-Dec		N/A	N/A	
			Placebo	21	05-Dec		N/A	N/A	
(Stoute et al., 2007)	Kenya		Imovax	20	32.9 ± 11.4	mean ± SD, tahun	13	65.00%	12 bulan
			FMP1/AS02A	20	33.7 ± 9.6		13	65.00%	
(Sulyok et al., 2021b)	Germany		PfSPZ	13	25 (19-42)	median (min-max), tahun	6	46.15%	8 bulan
			Saline (Placebo)	7	26 (21-36)		5	71.43%	
(Teuscher et al., 1994)	Tanzania	Grup 1b	Spf66	20	18-55	min-max, tahun	20	100.00%	8 bulan
			Placebo	10	18-55		10	100.00%	
		Grup 2	Spf66	25	01-May		17	68.00%	
			Placebo	25	01-May		7	28.00%	
(Thera et al., 2006)	Mali		FMP1/AS02A	20	40.3 ± 8	mean ± SD, tahun	15	75.00%	12 bulan
			Rabies	20	38.5 ± 10.1		18	90.00%	
(Thera et al., 2008)	Mali		FMP1/AS02A Half	20	26.1 ± 9.2	mean ± SD, tahun	16	80.00%	12 bulan
			FMP1/AS02A Full	20	29 ± 11.2		16	80.00%	
			Rabies vaccine	20	30.1 ± 12.2		17	85.00%	
(Thera et al., 2010)	Mali		FMP1/AS02A 10	15	3.5 ± 1.8	mean ± SD, tahun	8	53.33%	12 bulan
			FMP1/AS02A 25	30	3.5 ± 1.7		15	50.00%	

		FMP1/AS02A 50	30	3.6 ± 1.7		18	60.00%	
		Rabies	25	3.2 ± 1.9		10	40.00%	
(Thera et al., 2011)	Mali	FMP2.1/AS02A	199	3.4 ± 1.6	mean ± SD, tahun	96	48.24%	8 bulan
		Rabies	201	3.4 ± 1.5		89	44.28%	
(Thera et al., 2016)	Mali	PfAMA1	20	30.1 ± 10.6	mean ± SD, tahun	6	30.00%	12 bulan
		Tetanus Toxoid	20	26 ± 10.5		7	35.00%	
		R0.6C-AIOH	5	30		1	20.00%	
		R0.6C-AIOH+MM	5	28		3	60.00%	
		Pro.6C-AIOH	5	27		1	20.00%	
		Pro.6C-AIOH+MM	5	35		1	20.00%	
		Hepatitis B	5	33		2	40.00%	
(Tiono et al., 2024)	Burkina Faso	R0.6C-AIOH	20	30	mean, tahun	10	50.00%	6 bulan
		R0.6C-AIOH+MM	20	28		8	40.00%	
		Pro.6C-AIOH	20	29		9	45.00%	
		Pro.6C-AIOH+MM	20	29		11	55.00%	
		Hepatitis B	20	31		10	50.00%	
(Urdaneta et al., 1996)	Brazil	SPf66	400	Jul-60	min-max, tahun	247	61.75%	6 bulan
		Tetanus Toxoid	400	Jul-60		245	61.25%	
		RTS,S/AS01 + PHiD-CV	142	8.4 ± 0.8		83	58.45%	
		RTS,S/AS01 + HRV	142	8.3 ± 0.6	mean ± SD, minggu	73	51.41%	26 bulan
		RTS,S/AS01 alone	141	8.3 ± 0.7		74	52.48%	
		HBV + PHiD-CV	141	8.3 ± 0.7		60	42.55%	
		HBV+HRV	139	8.3 ± 0.7		76	54.68%	
(Valero et al., 1993)	Colombia	SPf66	738	N/A		392	53.12%	12 bulan
		Placebo	810	N/A		432	53.33%	
(Valero, 1996)	Colombia	SPf66	634	22.5 ± 18.8	mean ± SD, tahun	286	45.11%	22 bulan
		Placebo	523	20.7 ± 16.9		280	53.54%	
		Imovax	45	29.3 ± 10.4		18	40.00%	
(Withers et al., 2006)	Kenya	FMP1/AS02A 10	30	28.5 ± 9.6	mean ± SD, bulan	12	40.00%	12 bulan
		FMP1/AS02A 25	30	29.5 ± 10.9		11	36.67%	
		FMP1/AS02A 50	30	29.9 ± 9.9		17	56.67%	

Lampiran 4 Tabel luaran imunogenisitas

ID Studi	IgG	Grup	Intervensi	Waktu	N	GMT	LCI	UCI	ln(GMT)	ln(LCI)	ln(UCI)	SE	SD	Neff	Meandiff	SDdiff		
Abdulla 2008	Anti-CS		Hepatitis B	titik awal	152	0.4	0.3	0.4	-0.916	-1.204	-0.916	0.282	3.477	148	-0.288	4.985		
				bulan ke- 5	144	0.3	0.2	0.3	-1.204	-1.609	-1.204	0.397	4.764					
			RTS,S/AS02D	titik awal	141	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	3.349	142	5.445	5.892		
				bulan ke- 5	143	69.5	53.9	89.6	4.241	3.987	4.495	0.498	5.955					
Agnandji 2010	Anti-CS	pemberian 012	RTS,S/AS01E + EPI vaccine	titik awal	128	14.2	10.7	18.9	2.653	2.37	2.939	0.558	6.313	119	2.218	7.511		
				bulan ke- 3	112	130.4	95.9	177.3	4.871	4.563	5.178	0.603	6.382					
		pemberian 017		titik awal	117	16.1	12	21.8	2.779	2.485	3.082	0.585	6.328	108	2.226	7.248		
				bulan ke- 3	100	149.1	110.3	201.5	5.005	4.703	5.306	0.591	5.91					
		EPI vaccine	titik awal	118	25.4	18.4	35.1	3.235	2.912	3.558	0.633	6.876	106	2.059	7.747			
			bulan ke- 3	97	199.2	144.6	274.5	5.294	4.974	5.615	0.628	6.185						
Aponte 2007	Anti-CS		Engerix-B	titik awal	77	0.4	0.3	0.4	-0.916	-1.204	-0.916	0.282	2.475	72	-0.288	3.462		
				bulan ke- 4	68	0.3	0.2	0.3	-1.204	-1.609	-1.204	0.397	3.274					
			RTS,S/AS02D	titik awal	76	0.4	0.3	0.5	-0.916	-1.204	-0.693	0.501	4.368	73	6.214	5.336		
				bulan ke- 4	71	199.9	150.9	264.7	5.298	5.017	5.579	0.551	4.643					
Alonso 2004	Anti-CS	umur <24 bulan	Hepatitis B	titik awal	130	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0	130	0	0		
				bulan ke- 3	130	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0					
			RTS,S/AS02D	titik awal	454	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0	454	6.502	11.74		
				bulan ke- 3	454	199.9	150.9	264.7	5.298	5.017	5.579	0.551	11.74					
		umur >24 bulan	Hepatitis B	titik awal	144	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0	144	6.817	4.224		
				bulan ke- 3	144	274	229	328	5.613	5.434	5.793	0.352	4.224					
			RTS,S/AS02D	titik awal	457	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0	457	6.267	4.489		
				bulan ke- 3	457	158	142	176	5.063	4.956	5.17	0.21	4.489					
Bélard 2011	GMZ2		Rabies	titik awal	10	0.12	0.01	1.1	-2.12	-4.605	0.095	4.606	14.565	10	2.302	13.896		
				bulan ke- 3	10	1.2	0.57	2.5	0.182	-0.562	0.916	1.448	4.579					
			GMZ2-30	titik awal	10	2.3	0.7	7.8	0.833	-0.357	2.054	2.363	7.472	10	2.568	8.184		
				bulan ke- 3	10	30	11	83	3.401	2.398	4.419	1.981	6.264					
		GMZ2-100	titik awal	10	2.6	0.74	9.1	0.956	-0.301	2.208	2.459	7.776	10	1.988	8.753			
			bulan ke- 3	10	19	6.1	58	2.944	1.808	4.06	2.207	6.979						
		Bougouma, 2022	Anti-SE36	25-60 months	BK IM	titik awal	18	9.4	6.7	13	2.241	1.902	2.565	0.65	2.758	17	2.804	5.312
						bulan ke- 7	17	155.3	79.2	304.6	5.045	4.372	5.719	1.32	5.442			
BK SC	titik awal				18	15.1	8	28.8	2.715	2.079	3.36	1.255	5.325	18	2.418	6.13		
	bulan ke- 7				18	169.5	92.6	310.2	5.133	4.528	5.737	1.185	5.028					
Synflorix	titik awal				18	16.6	7.2	38.5	2.809	1.974	3.651	1.643	6.971	18	0.369	7.809		
	bulan ke- 7				18	24	11.4	50.5	3.178	2.434	3.922	1.458	6.186					
12-24 months	BK IM			titik awal	18	16.9	9.9	28.6	2.827	2.293	3.353	1.039	4.408	18	3.626	6.809		
				bulan ke- 7	18	634.6	284.3	1416	6.453	5.65	7.256	1.574	6.678					
	BK SC			titik awal	18	24.9	13.3	46.9	3.215	2.588	3.848	1.235	5.24	17	3.247	5.647		
				bulan ke- 7	16	640.2	374.8	1093	6.462	5.926	6.997	1.05	4.2					
Chitnis 2015	Anti-PfF2		JAIVAC A	titik awal	10	10	0.01	0.01	2.303	-4.605	-4.605	0	0	10	2.182	5.417		
				bulan ke- 7	10	88.7	37	212.5	4.485	3.611	5.359	1.713	5.417					
			JAIVAC B	titik awal	10	10.5	9.7	11.3	2.351	2.272	2.425	0.15	0.474	10	3.187	3.749		

Coulibaly 2022	anti-PfCSP		JAIVAC C	bulan ke- 7	10	254.1	136.2	473.9	5.538	4.914	6.161	1.222	3.864	10	4.054	6.033
				titik awal	10	12.3	9.9	15.3	2.51	2.293	2.728	0.426	1.347			
			Hepatitis B	bulan ke- 7	10	709.4	256.7	1960.6	6.564	5.548	7.581	1.992	6.299	15	0.243	3.863
				titik awal	15	10.2	9.8	10.7	2.322	2.282	2.37	0.086	0.333			
			PfSPZ-CVAc	bulan ke- 7	15	13	7.7	21.8	2.565	2.041	3.082	1.02	3.95	31	0.887	5.954
				titik awal	31	351.5	204.1	605.5	5.862	5.319	6.406	1.065	5.93			
			Saline	hari ke- 71	31	852.8	611.8	1189.9	6.749	6.416	7.082	0.653	3.636	31	0.038	3.615
				titik awal	31	210.2	165.7	266.6	5.348	5.11	5.586	0.466	2.595			
			Ad35 108	hari ke- 71	31	218.3	159.7	298.6	5.386	5.073	5.699	0.613	3.413	14	0.075	1.238
				titik awal	14	9	0.01	0.01	2.197	-4.605	-4.605	0	0			
			Ad35 109	bulan ke- 7	14	9.7	8.2	11.5	2.272	2.104	2.442	0.331	1.238	15	0.598	4.501
				titik awal	15	9.4	8.5	10.4	2.241	2.14	2.342	0.198	0.767			
Creech 2013	anti-CS		Ad35 1010	bulan ke- 7	15	17.1	9.2	31.5	2.839	2.219	3.45	1.206	4.671	15	0.838	4.694
				titik awal	15	9	0.01	0.01	2.197	-4.605	-4.605	0	0			
			Ad35 1011	bulan ke- 7	15	20.8	11.2	38.6	3.035	2.416	3.653	1.212	4.694	16	1.917	8.276
				titik awal	16	9	0.01	0.01	2.197	-4.605	-4.605	0	0			
			Saline	bulan ke- 7	16	61.2	21.3	175.9	4.114	3.059	5.17	2.069	8.276	12	0	0
				titik awal	12	9	0.01	0.01	2.197	-4.605	-4.605	0	0			
			RTS,S/AS01E	bulan ke- 7	12	9	0.01	0.01	2.197	-4.605	-4.605	0	0	79	6.537	3.136
				titik awal	85	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
			RTS,S/AS02D	bulan ke- 2	73	207	172	250	5.333	5.147	5.521	0.367	3.136	78	6.413	3.264
				titik awal	84	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
			RTS,S/AS01	bulan ke- 2	73	183	151	223	5.209	5.017	5.407	0.382	3.264	11	6.281	2.212
				titik awal	11	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
Leroux-Roels 2014	anti-CS		RTS,S/AS02	bulan ke- 3	11	160.3	114.1	225.4	5.077	4.737	5.418	0.667	2.212	11	5.553	3.201
				titik awal	11	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
			RTS,S/Saline	bulan ke- 3	11	77.4	47.3	126.7	4.349	3.857	4.842	0.965	3.201	12	3.705	6.298
				titik awal	12	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
			RTS,S/AS01	bulan ke- 3	12	12.2	4.8	30.7	2.501	1.569	3.424	1.818	6.298	80	7.001	4.101
				titik awal	81	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	2.538			
Owusu-Agyei 2009	anti-CS		Rabies	bulan ke- 3	79	329.2	260.6	415.8	5.797	5.563	6.03	0.458	4.071	72	0	2.409
				titik awal	73	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	2.409			
			RTS,S/AS02D	bulan ke- 3	71	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0	45	7.109	3.33
				titik awal	45	0.3	0.2	0.3	-1.204	-1.609	-1.204	0.397	2.663			
			RTS,S/AS01E	bulan ke- 3	45	367	293	459	5.905	5.68	6.129	0.44	2.952	90	7.653	3.031
				titik awal	90	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	2.675			
			Rabies	bulan ke- 3	90	632	554	720	6.449	6.317	6.579	0.257	2.438	45	0.288	4.377
				titik awal	45	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	1.892			
			RTS,S/AS02D	bulan ke- 3	45	0.4	0.3	0.6	-0.916	-1.204	-0.511	0.679	4.555	90	4.462	4.924
				titik awal	90	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
			RTS,S/AS01E	bulan ke- 7	90	26	20	34	3.258	2.996	3.526	0.519	4.924	90	5.136	4.389
				titik awal	90	0.3	0.3	0.4	-1.204	-1.204	-0.916	0.282	2.675			
Tiono 2024	R0.6C	dosis 50µg	R0.6C-AIOH	bulan ke- 7	90	51	40	64	3.932	3.689	4.159	0.461	4.373	5	1.386	8.037
				titik awal	5	2	0.5	8.5	0.693	-0.693	2.14	2.776	6.207			
			R0.6C-AIOH+MM	bulan ke- 2.5	5	8	1.5	41.9	2.079	0.405	3.735	3.263	7.296	5	2.388	6.613
				titik awal	5	3.8	0.8	17.7	1.335	-0.223	2.874	3.035	6.786			

Pro.6C	dosis 100µg	Hepatitis B	bulan ke- 2.5	5	41.4	19.1	89.7	3.723	2.95	4.496	1.515	3.388	5	-0.134	15.066
			titik awal	5	1.6	0.1	45.7	0.47	-2.303	3.822	6.003	13.423			
		R0.6C-AIOH	bulan ke- 2.5	5	1.4	0.1	23.5	0.336	-2.303	3.157	5.351	11.965	20	1.726	6.741
			titik awal	20	1.3	0.7	2.5	0.262	-0.357	0.916	1.248	5.581			
		R0.6C-AIOH+MM	bulan ke- 2.5	20	7.3	3.8	14.3	1.988	1.335	2.66	1.299	5.809	20	2.568	6.066
			titik awal	20	2.3	1.2	4.5	0.833	0.182	1.504	1.296	5.796			
		Hepatitis B	bulan ke- 2.5	20	30	18.5	48.6	3.401	2.918	3.884	0.947	4.235	20	0.041	10.582
			titik awal	20	2.4	1	5.8	0.875	0	1.758	1.723	7.705			
	dosis 50µg	Pro.6C-AIOH	bulan ke- 2.5	20	2.5	0.8	7.7	0.916	-0.223	2.041	2.219	9.924	5	1.457	4.345
			titik awal	5	1.7	0.7	4	0.531	-0.357	1.386	1.708	3.819			
		Pro.6C-AIOH+MM	bulan ke- 2.5	5	7.3	3.3	16.4	1.988	1.194	2.797	1.571	3.513	5	3.938	8.675
			titik awal	5	0.9	0.1	6.3	-0.105	-2.303	1.841	4.061	9.081			
		Hepatitis B	bulan ke- 2.5	5	46.2	22.4	95.5	3.833	3.109	4.559	1.421	3.177	5	0	6.75
			titik awal	5	2	1	4.3	0.693	0	1.459	1.43	3.198			
		Pro.6C-AIOH	bulan ke- 2.5	5	2	0.5	12.1	0.693	-0.693	2.493	3.122	6.981	20	1.61	5.83
			titik awal	20	2	1.3	3.1	0.693	0.262	1.131	0.852	3.81			
	dosis 100µg	Pro.6C-AIOH+MM	bulan ke- 2.5	20	10	5.2	19.1	2.303	1.649	2.95	1.275	5.702	20	3.654	2.705
			titik awal	20	1.6	1.2	2.2	0.47	0.182	0.788	0.594	2.656			
		Hepatitis B	bulan ke- 2.5	20	61.8	50.7	75.5	4.124	3.926	4.324	0.39	1.744	20	0.789	5.845
			titik awal	20	1.5	0.9	2.6	0.405	-0.105	0.956	1.04	4.651			
Thera 2006	anti-MSP-142	FMP1/AS02A	bulan ke- 2.5	20	3.3	1.8	5.9	1.194	0.588	1.775	1.163	5.201	20	1.867	6.703
			titik awal	20	5858	2650	12950	8.676	7.882	9.469	1.555	6.954			
		Rabies	bulan ke- 3	20	37923	26788	53686	10.543	10.196	10.891	0.681	3.046	20	0.742	7.766
			titik awal	20	3282	1423	7568	8.096	7.261	8.932	1.638	7.325			
Thera 2016	PfAMA1	PfAMA1	bulan ke- 3	20	6892	3645	13029	8.838	8.201	9.475	1.249	5.586	19	1.226	6.728
			titik awal	20	5164	2494	10691	8.549	7.822	9.277	1.426	6.377			
		Tetanus Toxoid	bulan ke- 3	18	17584	9889	31267	9.775	9.199	10.35	1.128	4.786	19	-0.128	7.838
			titik awal	20	9938	4484	22025	9.204	8.408	10	1.56	6.977			
Ouédraogo 2023	anti-SE36	KB-SE36/CpG	bulan ke- 3	18	8744	4184	18726	9.076	8.339	9.838	1.469	6.232	19	1.096	9.21
			titik awal	30	79.7	37.1	170.9	4.378	3.614	5.141	1.496	8.194			
		Rabies	bulan ke- 4	29	238.3	119	477.2	5.474	4.779	6.168	1.361	7.329	15	0.445	7.109
			titik awal	15	84.8	41.9	171.6	4.44	3.735	5.145	1.382	5.352			
		KB-SE36/CpG	bulan ke- 4	15	132.3	55.8	313.8	4.885	4.022	5.749	1.692	6.553	30	1.989	3.546
			titik awal	30	37.3	27.1	51.4	3.619	3.3	3.94	0.627	3.434			
		Rabies	bulan ke- 4	30	272.5	218.1	340.4	5.608	5.385	5.83	0.436	2.388	15	0.789	10.963
			titik awal	15	44.8	23.5	85.4	3.802	3.157	4.447	1.264	4.895			
		KB-SE36/CpG	bulan ke- 4	15	98.6	22	441.8	4.591	3.091	6.091	2.94	11.387	31	3.598	5.388
			titik awal	31	23.5	14.7	37.5	3.157	2.688	3.624	0.917	5.106			
		Rabies	bulan ke- 4	31	858.5	604.1	1220.2	6.755	6.404	7.107	0.689	3.836	14	0.129	6.599
			titik awal	14	21.1	8.2	53.9	3.049	2.104	3.987	1.845	6.903			
RTS,S 2011	anti-CS	RTS,S/AS01	bulan ke- 4	14	24	17.1	33.9	3.178	2.839	3.523	0.67	2.507	200	7.636	1.344
			titik awal	200	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			
		Rabies	bulan ke- 1	200	621.2	591.7	652.1	6.432	6.383	6.48	0.095	1.344	200	0	0
			titik awal	200	0.3	0.3	0.3	-1.204	-1.204	-1.204	0	0			

Lampiran 5 Tabel luaran keamanan untuk nyeri di lokasi injeksi

ID Studi	Intervensi	Waktu Ukur	Pelaporan	Kelompok	Nyeri di lokasi injeksi			
					Data awal		Konversi	
					Total	Kejadian	Total	Kejadian
Abdulla 2008	Hepatitis B	9 bulan	Dosis		492	416	164	139
	RTS,S/AS02D				490	416	164	139
Aponte 2007	Hepatitis B	14 bulan	Subjek		106	95	106	95
	RTS,S/AS02B				105	103	105	103
Alonso 2004	RTS,S/AS02A	12 bulan	Subjek	Umur <24	701	205	701	205
	RTS,S/AS02A			Umur >24	2225	539	2225	539
	Control			Umur <24	695	52	695	52
	Control			Umur >24	2217	90	2217	90
Arévalo-Herrera 2022	PvCS protein	10 bulan	Dosis	Fase IIa	33	14	11	5
	Placebo			(Naive)	15	8	5	3
	PvCS protein			Fase IIb	33	7	11	3
	Placebo			(Semi)	15	3	5	1
Bejon 2008a	RTS,S/AS01E	10.5 bulan	Dosis		1320	172	440	58
	Rabies				1320	157	440	53
Bojang 2001	RTS,S/AS02	6 bulan	Dosis		435	378	145	126
	Control				430	228	144	76
Bojang 2005	Rabies	4 bulan	Dosis	Kohort 1 (6-11 tahun)	90	74	30	25
	RTS,S/AS02A 10µg				60	53	20	18
	RTS,S/AS02A 25µg				59	53	20	18
	RTS,S/AS02A 50µg				60	59	20	20
	Rabies			Kohort 2 (1-5 tahun)	125	104	42	35
	RTS,S/AS02A 10µg				89	70	30	24
	RTS,S/AS02A 25µg				89	75	30	25
	RTS,S/AS02A 50µg				89	82	30	28
Bougouma 2022	BK-SE36 IM	12 bulan	Dosis	Kohort 1 (25-60 bulan)	51	22	17	8
	BK-SE36 SC				54	40	18	14
	Control				54	23	18	8
	BK-SE36 IM			Kohort 2 (12-24 bulan)	54	18	18	6
	BK-SE36 SC				53	28	18	10
	Control				54	14	18	5
Chitnis 2015	JAIVAC 10	12 bulan	Subjek		10	9	10	9
	JAIVAC 25				10	10	10	10
	JAIVAC 50				10	9	10	9
Coulibaly 2022	Hepatitis B	11 bulan	Subjek		15	5	15	5
	PfSPZ-C				31	15	31	15
	Control				31	9	31	9
Cummings 2024	RTS,S + FMP1-separate	4.5 bulan	Dosis		44	22	15	8
	RTS,S + FMP1-same				44	14	15	5
	FMP1-alone				44	14	15	5
	RTS,S-alone				43	8	15	3
Ezoe 2020	BK-SE36/CpG	12 bulan	Subjek	Dosis separuh	7	7	7	7

	Placebo			3	1	3	1
	BK-SE36/CpG			11	11	11	11
	Placebo		Dosis penuh	5	0	5	0
Lell 2009	RTS,S/AS01E	14 bulan	Dosis	261	126	87	42
	RTS,S/AS02D			262	142	88	48
Lusingu 2009	MSP3 15	3 bulan	Dosis	45	6	15	2
	MSP3 30			45	4	15	2
	Hepatitis B			45	4	15	2
Lusingu 2010	RTS,S/AS01E	14 bulan	Dosis	1320	172	440	58
	Rabies			1318	157	440	53
Macete 2007b	Engerix-B	16 bulan	Dosis	83	3	28	1
	RTS,S/AS02A			84	25	28	9
	PfCP-2.9 5			20	5	20	5
Malkin, 2008	PfCP-2.9 20	8 bulan	Subjek	20	2	20	2
	PfCP-2.9 50			20	7	20	7
	Control			10	2	10	2
Moorthy 2004	ME-TRAP	4 bulan	Subjek	152	103	152	103
	Rabies			157	19	157	19
Mordmüller 2010	Rabies	12 bulan	Dosis	60	19	20	7
	GMZ2			60	41	20	14
Ogutu 2009	FMP1/AS02	8 bulan	Subjek	200	175	200	175
	Rabipur			200	14	200	14
	RTS,S/AS01B			242	132	81	44
Polhemus 2009	RTS,S/AS02A	12 bulan	Dosis	247	166	83	56
	Rabies			247	68	83	23
	PfAMA1 Alum 10			10	8	10	8
	PfAMA1 Alum 50			10	10	10	10
Roestenberg 2008	PfAMA1 Mon 10	12 bulan	Subjek	10	8	10	8
	PfAMA1 Mon 50			9	9	9	9
	PfAMA1 AS02 10			9	9	9	9
	PfAMA1 AS02 50			8	8	8	8
RTS,S 2011	RTS,S/AS01	24 bulan	Dosis	4321	534	1441	178
	Rabies			2128	124	710	42
	EBA 5			18	14	18	14
	EBA 20			18	16	18	16
Sahly 2010	EBA 80	12 bulan	Subjek	18	17	18	17
	EBA 160			18	17	18	17
	Placebo			8	1	8	1
Sirima 2007	MSP3-LSP	12 bulan	Dosis	45	16	15	6
	Tetanus			45	18	15	6
	MSP3 15			45	27	15	9
Sirima 2009	MSP3 30	12 bulan	Dosis	45	27	15	9
	Engerix B			45	5	15	2
	PfSPZ 4.5			8	0	8	0
Sirima 2022	PfSPZ 9	18 bulan	Subjek	8	0	8	0
	PfSPZ 1.8			8	0	8	0

	PfSPZ 2.7A				8	0	8	0
	PfSPZ 2.7B				39	1	39	1
	Placebo				41	1	41	1
Sissoko 2017	PfSPZ	10 bulan	Subjek		60	4	60	4
	Placebo				60	6	60	6
Sissoko 2022	PfSPZ	8 bulan	Subjek		46	0	46	0
	Placebo				47	4	47	4
Steinhardt 2020	PfSPZ 4.5	18 bulan	Subjek	Grup 1 (5-9 tahun)	8	1	8	1
	PfSPZ 9				8	0	8	0
	PfSPZ 18				8	0	8	0
	Placebo				12	2	12	2
	PfSPZ 1.35			Grup 2 (13-59 bulan)	10	1	10	1
	PfSPZ 2.7				9	0	9	0
	PfSPZ 4.5				8	0	8	0
	PfSPZ 9				9	1	9	1
	PfSPZ 18				8	1	8	1
	Placebo				20	2	20	2
	PfSPZ 1.35			Grup 3 (5-12 bulan)	8	0	8	0
	PfSPZ 2.7				10	0	10	0
	PfSPZ 4.5				8	1	8	1
	PfSPZ 9				10	2	10	2
	PfSPZ 18				8	0	8	0
	Placebo				21	2	21	2
Stoute 2007	Imovax	12 bulan	Dosis		58	31	20	11
	FMP1/AS02A				59	41	20	14
Teuscher 1994	SPf66	7.5 bulan	Dosis	Fase 1b	67	13	23	5
	Placebo				55	5	19	2
	SPf66			Fase 2	54	37	18	13
	Placebo				29	10	10	4
Thera 2006	FMP1/AS02A	12 bulan	Dosis		60	23	20	8
	Rabies				60	6	20	2
Thera 2008	FMP1/AS02A Half	12 bulan	Dosis		60	45	20	15
	FMP1/AS02A Full				59	53	20	18
	Rabies				60	16	20	6
Thera 2010	FMP1/AS02A 10	12 bulan	Dosis		44	18	15	6
	FMP1/AS02A 25				87	46	29	16
	FMP1/AS02A 50				85	51	29	17
	Rabies				73	7	25	3
Thera 2011	FMP2.1/AS02A	12 bulan	Subjek		199	190	199	190
	Rabies				201	108	201	108
Thera 2016	PfAMA1	12 bulan	Dosis		60	27	20	9
	Tetanus				60	12	20	4
Tiono 2024	R0.6C-AIOH	8 bulan	Dosis	Dosis rendah (30 µg)	15	0	5	0
	R0.6C-AIOH/MM				15	1	5	1
	ProC6C-AIOH				15	1	5	1
	ProC6C-AIOH/MM				15	0	5	0

	Control			15	0	5	0
	R0.6C-AIOH			58	10	20	4
	R0.6C-AIOH/MM			59	12	20	4
	ProC6C-AIOH			59	12	20	4
	ProC6C-AIOH/MM			60	22	20	8
	Control			60	4	20	2
Urdaneta 1996	SPf66	6.5 bulan	Dosis	932	26	311	9
	Tetanus			911	26	304	9
Valea 2018	RTS,S/AS01 alone	10 bulan	Dosis	423	66	141	22
	HBV+HRV			385	31	129	11
	Imovax			127	5	43	2
Withers 2006	FMP1/AS02A 10	8 bulan	Dosis	88	12	30	4
	FMP1/AS02A 25			88	36	30	12
	FMP1/AS02A 50			84	54	28	18

Lampiran 6 Tabel luaran keamanan untuk efek samping demam

ID Studi	Intervensi	Waktu Ukur	Pelaporan	Kelompok	Demam			
					Data awal		Konversi	
					Total	Kejadian	Total	Kejadian
Abdulla 2008	Hepatitis B	9 bulan	Dosis		492	67	164	23
	RTS,S/AS02D				490	145	164	49
Agnandji 2010	RTS,S/AS01E (012)	8 bulan	Dosis		667	150	223	50
	RTS,S/AS01E (017)				663	154	221	52
	Control				661	94	221	32
Alonso 2004	RTS,S/AS02A	12 bulan	Subjek	Umur <24 bulan	701	192	701	192
	RTS,S/AS02A			Umur >24 bulan	2225	230	2225	230
	Control			Umur <24 bulan	695	41	695	41
	Control			Umur >24 bulan	2217	139	2217	139
Aponte 2007	Hepatitis B	14 bulan	Subjek		106	5	106	5
	RTS,S/AS02B				105	11	105	11
Arévalo-Herrera 2022	PvCS protein	10 bulan	Dosis	Fase IIa (Naive)	33	2	11	1
	Placebo				15	2	5	1
	PvCS protein			Fase IIb (Semi)	33	1	11	1
	Placebo				15	1	5	1
Asante 2020	RTS,S coadministration	4.5 bulan	Subjek		221	54	221	54
	RTS,S alone				229	50	229	50
	Control				225	17	225	17
Bejon 2008a	RTS,S/AS01E	10.5 bulan	Dosis		1320	149	440	50
	Rabies				1318	409	440	137
Bojang 2001	RTS,S/AS02	6 bulan	Dosis		435	13	145	5
	Control				430	6	144	2
Bojang 2005	Rabies	4 bulan	Dosis	Kohort 1 (6-11 tahun)	90	5	30	2
	RTS,S/AS02A 10µg				60	6	20	2
	RTS,S/AS02A 25µg				59	5	20	2
	RTS,S/AS02A 50µg				60	6	20	2
	Rabies			Kohort 2 (1-5 tahun)	125	24	42	8
	RTS,S/AS02A 10µg				89	10	30	4
	RTS,S/AS02A 25µg				89	8	30	3
	RTS,S/AS02A 50µg				89	15	30	5
Bougouma 2022	BK-SE36 IM	12 bulan	Dosis	Kohort 1 (25-60 bulan)	51	1	17	1
	BK-SE36 SC				54	2	18	1
	Control				54	3	18	1
	BK-SE36 IM			Kohort 2 (12-24 bulan)	54	3	18	1
	BK-SE36 SC				53	2	18	1
	Control				54	2	18	1
Chitnis 2015	JAIVAC 10	12 bulan	Subjek		10	0	10	0
	JAIVAC 25				10	0	10	0
	JAIVAC 50				10	0	10	0
	Hepatitis B				15	1	15	1
Coulibaly 2022	PFSPZ-C	11 bulan	Subjek		31	0	31	0

	Control				31	1	31	1
	RTS,S + FMP1-separate				43	7	15	3
Cummings 2024	RTS,S + FMP1-same	4.5 bulan	Dosis		44	6	15	2
	FMP1-alone				44	5	15	2
	RTS,S-alone				43	5	15	2
Lell 2009	RTS,S/AS01E	14 bulan	Dosis		261	15	87	5
	RTS,S/AS02D				262	23	88	8
Lusingu 2009	MSP3 15	3 bulan	Dosis		45	2	15	1
	MSP3 30				45	3	15	1
	Hepatitis B				45	4	15	2
Lusingu 2010	RTS,S/AS01E	14 bulan	Dosis		1320	149	440	50
	Rabies				1318	409	440	137
Macete 2007b	Engerix-B	16 bulan	Dosis		83	3	28	1
	RTS,S/AS02A				84	12	28	4
	PfCP-2.9 5				20	0	20	0
	PfCP-2.9 20				20	0	20	0
Malkin, 2008	PfCP-2.9 50	8 bulan	Subjek		20	0	20	0
	Control				10	0	10	0
Moorthy 2004	ME-TRAP	4 bulan	Subjek		161	6	161	6
	Rabies				168	0	168	0
Mordmüller 2010	Rabies	12 bulan	Dosis		60	0	20	0
	GMZ2				60	0	20	0
Ogutu 2009	FMP1/AS02	8 bulan	Subjek		200	135	200	135
	Rabipur				200	61	200	61
	BK-SE36/CpG			Kohort 1	89	1	30	1
	Rabies			(21-45 tahun)	45	0	15	0
Ouédraogo 2023	BK-SE36/CpG	12 bulan	Dosis	Kohort 2	90	4	30	2
	Rabies			(5-10 tahun)	45	0	15	0
	BK-SE36/CpG			Kohort 3	93	19	31	7
	Rabies			(12-24 bulan)	42	1	14	1
Polhemus 2009	RTS,S/AS01B	12 bulan	Dosis		242	21	81	7
	RTS,S/AS02A				247	14	83	5
	Rabies				247	12	83	4
	PfAMA1 Alum 10				10	0	10	0
	PfAMA1 Alum 50				10	0	10	0
Roestenberg 2008	PfAMA1 Mon 10	12 bulan	Subjek		10	0	10	0
	PfAMA1 Mon 50				9	0	9	0
	PfAMA1 AS02 10				9	5	9	5
	PfAMA1 AS02 50				8	5	8	5
RTS,S 2011	RTS,S/AS01	24 bulan	Dosis		4321	1345	1441	449
	Rabies				2128	285	710	95
RTS,S 2012	RTS,S/AS01	14 bulan	Dosis		4252	129	1418	43
	MenC				2169	457	723	153
	EBA 5				18	0	18	0
Sahly 2010	EBA 20	12 bulan	Subjek		18	1	18	1
	EBA 80				18	1	18	1

	EBA 160				18	1	18	1
	Placebo				8	0	8	0
Sirima 2007	MSP3-LSP	12 bulan	Dosis		45	1	15	1
	Tetanus				45	1	15	1
Sirima 2009	MSP3 15	12 bulan	Dosis		45	1	15	1
	MSP3 30				45	9	15	3
	Engerix B				45	9	15	3
Sirima 2022	PfSPZ 4.5	18 bulan	Subjek		8	0	8	0
	PfSPZ 9				8	0	8	0
	PfSPZ 1.8				8	0	8	0
	PfSPZ 2.7A				8	0	8	0
	PfSPZ 2.7B				39	1	39	1
	Placebo				41	0	41	0
Sissoko 2022	PfSPZ	8 bulan	Subjek		46	0	46	0
	Placebo				47	1	47	1
Steinhardt 2020	PfSPZ 4.5	18 bulan	Subjek	Grup 1 (5-9 tahun)	8	1	8	1
	PfSPZ 9				8	1	8	1
	PfSPZ 18				8	1	8	1
	Placebo				12	4	12	4
	PfSPZ 1.35			Grup 2 (13-59 bulan)	10	2	10	2
	PfSPZ 2.7				9	0	9	0
	PfSPZ 4.5				8	0	8	0
	PfSPZ 9				9	1	9	1
	PfSPZ 18				8	2	8	2
	Placebo				20	2	20	2
	PfSPZ 1.35			Grup 3 (5-12 bulan)	8	0	8	0
	PfSPZ 2.7				10	0	10	0
	PfSPZ 4.5				8	2	8	2
	PfSPZ 9				10	2	10	2
	PfSPZ 18				8	2	8	2
	Placebo				21	4	21	4
Stoute 2007	Imovax	12 bulan	Dosis		58	2	20	1
	FMP1/AS02A				59	1	20	1
Teuscher 1994	SPf66	7.5 bulan	Dosis		67	23	23	8
	Placebo				55	11	19	4
	SPf66				54	4	18	2
Thera 2006	Placebo	12 bulan	Dosis		29	0	10	0
	FMP1/AS02A				60	7	20	3
Thera 2008	Rabies	12 bulan	Dosis		60	3	20	1
	FMP1/AS02A Half				60	6	20	2
	FMP1/AS02A Full				59	6	20	2
Thera 2010	Rabies	12 bulan	Dosis		60	1	20	1
	FMP1/AS02A 10				44	0	15	0
	FMP1/AS02A 25				87	21	29	7
	FMP1/AS02A 50				85	20	29	7
	Rabies				73	6	25	2

Thera 2011	FMP2.1/AS02A	12 bulan	Subjek		199	122	199	122
	Rabies				201	52	201	52
Thera 2016	PfAMA1	12 bulan	Dosis		60	2	20	1
	Tetanus				60	5	20	2
Tiono 2024	R0.6C-AIOH	8 bulan	Dosis	Dosis rendah (30 µg)	15	0	5	0
	R0.6C-AIOH/MM				15	2	5	1
	ProC6C-AIOH				15	2	5	1
	ProC6C-AIOH/MM				15	1	5	1
	Control				15	1	5	1
	R0.6C-AIOH			Dosis tinggi (100 µg)	58	1	20	1
	R0.6C-AIOH/MM				59	0	20	0
	ProC6C-AIOH				59	2	20	1
	ProC6C-AIOH/MM				60	0	20	0
	Control				60	1	20	1
Urdaneta 1996	SPf66	6.5 bulan	Dosis		932	20	311	7
	Tetanus				911	16	304	6
Valea 2018	RTS,S/AS01 alone	10 bulan	Dosis		423	60	141	20
	HBV+HRV				385	30	129	10
Withers 2006	Imovax	8 bulan	Dosis		127	22	43	8
	FMP1/AS02A 10				88	16	30	6
	FMP1/AS02A 25				88	15	30	5
	FMP1/AS02A 50				84	24	28	8

Lampiran 7 Tabel luaran efikasi

ID Studi	Waktu Ukur	Intervensi	Total	Kejadian
Abdulla 2008	9 bulan	Hepatitis B	151	20
		RTS,S/AS02D	146	8
Alonso 2004	8.5 bulan	Hepatitis B	745	176
		RTS,S/AS02A	745	137
Aponte 2007	6 bulan	Engerix-B	92	22
		RTS,S/AS02D	93	9
Bejon 2008a	8 bulan	RTS,S/A10E	402	33
		Rabies	407	70
Bojang 1998	18 bulan	SPf66	269	165
		IPV	204	121
Polhemus 2009	6 bulan	RTS,S/AS01B	74	28
		RTS,S/AS02A	79	28
		Rabies	153	56
RTS,S 2011	18 bulan	RTS,S/AS01	2830	1210
		Rabies	1466	883
RTS,S 2012	18 bulan	RTS,S/AS01	3995	1475
		MenC	2008	879
Valero 1993	3 bulan	SPf66	738	23
		Placebo	810	46

Lampiran 8 Tabel perbandingan hasil luaran imunogenisitas

Treatment	Ad35	BK-SE36-IM	BK-SE36-SC	Control	FMP1/AS02A	GMZ2	JAIVAC	PfAMA1
Ad35	Ad35	.	.	1.92 (-4.86, 8.69)	.	.	.	.
BK-SE36-IM	-0.71 (-8.19, 6.76)	BK-SE36-IM	0.38 (-4.37, 5.14)	2.61 (-0.55, 5.77)	.	.	.	.
BK-SE36-SC	-0.84 (-8.92, 7.24)	-0.12 (-4.52, 4.27)	BK-SE36-SC	3.20 (-1.56, 7.97)	.	.	.	.
Control	1.92 (-4.86, 8.69)	2.63 (-0.52, 5.78)	2.75 (-1.64, 7.15)	Control	-1.12 (-8.17, 5.92)	-0.27 (-11.64, 11.11)	-3.81 (-10.69, 3.06)	-1.35 (-8.50, 5.79)
FMP1/AS02A	0.79 (-8.99, 10.57)	1.51 (-6.22, 9.23)	1.63 (-6.68, 9.94)	-1.13 (-8.17, 5.92)	FMP1/AS02A	.	.	.
GMZ2	1.65 (-11.59, 14.89)	2.36 (-9.44, 14.17)	2.49 (-9.71, 14.68)	-0.27 (-11.64, 11.11)	0.86 (-12.52, 14.24)	GMZ2	.	.
JAIVAC	-1.89 (-11.55, 7.76)	-1.18 (-8.75, 6.38)	-1.06 (-9.22, 7.11)	-3.81 (-10.69, 3.06)	-2.69 (-12.53, 7.16)	-3.55 (-16.84, 9.75)	JAIVAC	.
PfAMA1	0.56 (-9.29, 10.41)	1.28 (-6.53, 9.09)	1.40 (-6.99, 9.79)	-1.35 (-8.50, 5.79)	-0.23 (-10.27, 9.81)	-1.09 (-14.52, 12.34)	2.46 (-7.46, 12.37)	PfAMA1
PfSPZ	1.07 (-7.96, 10.09)	1.78 (-4.96, 8.52)	1.91 (-5.50, 9.31)	-0.85 (-6.81, 5.11)	0.28 (-8.95, 9.51)	-0.58 (-13.42, 12.26)	2.96 (-6.14, 12.06)	0.50 (-8.80, 9.81)
Pro.6C-AIOH	0.89 (-7.68, 9.47)	1.61 (-4.51, 7.73)	1.73 (-5.12, 8.58)	-1.02 (-6.27, 4.23)	0.10 (-8.69, 8.89)	-0.76 (-13.28, 11.77)	2.79 (-5.86, 11.44)	0.33 (-8.53, 9.20)
Pro.6C-AIOH+MM	-1.21 (-9.83, 7.41)	-0.49 (-6.69, 5.70)	-0.37 (-7.28, 6.54)	-3.12 (-8.46, 2.21)	-2.00 (-10.84, 6.84)	-2.86 (-15.42, 9.70)	0.69 (-8.01, 9.39)	-1.77 (-10.69, 7.14)
R0.6C-AIOH	0.27 (-9.42, 9.96)	0.98 (-6.63, 8.59)	1.11 (-7.10, 9.31)	-1.65 (-8.58, 5.28)	-0.52 (-10.41, 9.36)	-1.38 (-14.70, 11.94)	2.16 (-7.60, 11.92)	-0.29 (-10.25, 9.66)
R0.6C-AIOH+MM	-0.62 (-10.22, 8.98)	0.10 (-7.40, 7.59)	0.22 (-7.88, 8.32)	-2.54 (-9.33, 4.26)	-1.41 (-11.20, 8.38)	-2.27 (-15.52, 10.98)	1.28 (-8.39, 10.94)	-1.18 (-11.04, 8.68)
RTSS	-0.62 (-9.89, 8.64)	0.09 (-6.97, 7.15)	0.22 (-7.48, 7.91)	-2.54 (-8.86, 3.78)	-1.41 (-10.88, 8.05)	-2.27 (-15.28, 10.74)	1.27 (-8.06, 10.61)	-1.19 (-10.72, 8.35)
RTSS/AS01	-3.11 (-10.28, 4.06)	-2.39 (-6.32, 1.53)	-2.27 (-7.25, 2.71)	-5.02 (-7.36, -2.68)	-3.90 (-11.33, 3.53)	-4.76 (-16.37, 6.86)	-1.21 (-8.48, 6.05)	-3.67 (-11.19, 3.85)
RTSS/AS02	-2.57 (-9.70, 4.55)	-1.86 (-5.70, 1.98)	-1.74 (-6.65, 3.18)	-4.49 (-6.68, -2.30)	-3.36 (-10.75, 4.02)	-4.22 (-15.81, 7.36)	-0.68 (-7.90, 6.54)	-3.14 (-10.61, 4.34)
Treatment	PfSPZ	Pro.6C-AIOH	Pro.6C-AIOH+MM	R0.6C-AIOH	R0.6C-AIOH+MM	RTSS	RTSS/AS01	RTSS/AS02
Ad35	.	.	.	.	.	.	.	.
BK-SE36-IM	.	.	.	.	.	.	.	.
BK-SE36-SC	.	.	.	.	.	.	.	.
Control	-0.85 (-6.81, 5.11)	-1.04 (-6.30, 4.22)	-3.12 (-8.47, 2.24)	-1.65 (-8.61, 5.30)	-2.53 (-9.36, 4.30)	.	-5.04 (-7.84, -2.25)	-4.44 (-6.94, -1.95)
FMP1/AS02A	.	.	.	.	.	.	.	.
GMZ2	.	.	.	.	.	.	.	.
JAIVAC	.	.	.	.	.	.	.	.

PfAMA1								
PfSPZ	PfSPZ							
Pro.6C-AIOH	-0.17 (-8.11, 7.77)	Pro.6C-AIOH	-2.16 (-7.39, 3.07)					
Pro.6C-AIOH+MM	-2.28 (-10.27, 5.72)	-2.10 (-7.28, 3.07)	Pro.6C-AIOH+MM					
R0.6C-AIOH	-0.80 (-9.94, 8.34)	-0.63 (-9.32, 8.07)	1.48 (-7.26, 10.22)	R0.6C-AIOH	-0.89 (-6.57, 4.80)			
R0.6C-AIOH+MM	-1.69 (-10.72, 7.35)	-1.51 (-10.10, 7.07)	0.59 (-8.05, 9.23)	-0.89 (-6.57, 4.79)	R0.6C-AIOH+MM			
RTSS	-1.69 (-10.37, 6.99)	-1.52 (-9.73, 6.69)	0.58 (-7.68, 8.85)	-0.89 (-10.27, 8.48)	-0.00 (-9.28, 9.27)	RTSS	-2.58 (-9.20, 4.05)	-1.85 (-8.61, 4.92)
RTSS/AS01	-4.17 (-10.58, 2.23)	-4.00 (-9.75, 1.75)	-1.90 (-7.72, 3.92)	-3.38 (-10.69, 3.94)	-2.49 (-9.68, 4.70)	-2.48 (-8.59, 3.63)	RTSS/AS01	0.51 (-2.31, 3.33)
RTSS/AS02	-3.64 (-9.99, 2.71)	-3.47 (-9.16, 2.22)	-1.37 (-7.13, 4.40)	-2.84 (-10.11, 4.42)	-1.95 (-9.10, 5.19)	-1.95 (-8.08, 4.18)	0.53 (-1.81, 2.88)	RTSS/AS02

Catatan: Hasil perbandingan ditampilkan dalam bentuk nilai risiko relatif dengan interval kepercayaan 95% dalam tanda kurung. Perbandingan langsung ditampilkan di atas label intervensi dan perbandingan tidak langsung ditampilkan di bawah label intervensi. Pewarnaan dalam kotak menunjukkan penilaian risiko bias (hijau = *low*, kuning = *some concerns*, merah = *high*)

Lampiran 9 Tabel perbandingan hasil luaran nyeri di lokasi injeksi

Treatment	BK-SE36	Control	EBA	FMP1/AS02	FMP2.1/AS02	GMZ2	JAIVAC	ME-TRAP	MSP3	PfAMA1
BK-SE36	BK-SE36	1.55 (0.65, 3.70)	.	.	.	.	.	.	.	.
Control	1.55 (0.65, 3.70)	Control	0.14 (0.01, 1.39)	0.24 (0.12, 0.48)	0.56 (0.14, 2.24)	0.50 (0.11, 2.30)	0.36 (0.08, 1.69)	0.18 (0.04, 0.75)	0.62 (0.22, 1.82)	0.44 (0.08, 2.43)
EBA	0.22 (0.02, 2.53)	0.14 (0.01, 1.39)	EBA	.	.	.	.	.	.	.
FMP1/AS02	0.38 (0.13, 1.13)	0.24 (0.12, 0.48)	1.73 (0.16, 18.85)	FMP1/AS02	.	.	.	.	.	.
FMP2.1/AS02	0.87 (0.17, 4.46)	0.56 (0.14, 2.24)	4.00 (0.28, 58.13)	2.31 (0.50, 10.75)	FMP2.1/AS02	.	.	.	.	.
GMZ2	0.77 (0.13, 4.49)	0.50 (0.11, 2.30)	3.56 (0.23, 55.82)	2.06 (0.39, 10.89)	0.89 (0.11, 6.95)	GMZ2	.	.	.	.
JAIVAC	0.55 (0.09, 3.28)	0.36 (0.08, 1.69)	2.54 (0.16, 40.47)	1.47 (0.27, 7.98)	0.63 (0.08, 5.06)	0.71 (0.08, 6.29)	JAIVAC	.	.	.
ME-TRAP	0.28 (0.05, 1.49)	0.18 (0.04, 0.75)	1.27 (0.08, 19.05)	0.73 (0.15, 3.60)	0.32 (0.04, 2.33)	0.36 (0.04, 2.91)	0.50 (0.06, 4.16)	ME-TRAP	.	.
MSP3	0.97 (0.24, 3.84)	0.62 (0.22, 1.82)	4.44 (0.35, 55.70)	2.57 (0.73, 9.07)	1.11 (0.19, 6.35)	1.25 (0.19, 8.04)	1.75 (0.27, 11.50)	3.50 (0.58, 21.02)	MSP3	.
PfAMA1	0.69 (0.10, 4.65)	0.44 (0.08, 2.43)	3.16 (0.18, 54.87)	1.83 (0.29, 11.38)	0.79 (0.09, 7.06)	0.89 (0.09, 8.73)	1.24 (0.12, 12.44)	2.49 (0.27, 23.12)	0.71 (0.10, 5.29)	PfAMA1
PfCP	1.33 (0.16, 10.81)	0.86 (0.13, 5.77)	6.10 (0.31, 120.20)	3.53 (0.47, 26.62)	1.52 (0.14, 16.03)	1.71 (0.15, 19.70)	2.40 (0.21, 28.05)	4.80 (0.44, 52.38)	1.37 (0.15, 12.19)	1.93 (0.15, 24.81)
PfSPZ	2.19 (0.66, 7.24)	1.41 (0.62, 3.21)	10.04 (0.88, 114.64)	5.81 (2.01, 16.79)	2.51 (0.50, 12.50)	2.83 (0.50, 15.96)	3.96 (0.68, 22.88)	7.91 (1.51, 41.53)	2.26 (0.59, 8.68)	3.18 (0.48, 20.99)
ProC6C-AIOH	0.62 (0.07, 5.84)	0.40 (0.05, 3.16)	2.84 (0.13, 62.28)	1.65 (0.19, 14.45)	0.71 (0.06, 8.53)	0.80 (0.06, 10.43)	1.12 (0.08, 14.84)	2.24 (0.18, 27.82)	0.64 (0.06, 6.55)	0.90 (0.06, 13.07)
ProC6C-AIOH/MM	0.39 (0.04, 3.42)	0.25 (0.03, 1.84)	1.78 (0.09, 37.14)	1.03 (0.13, 8.45)	0.44 (0.04, 5.03)	0.50 (0.04, 6.16)	0.70 (0.06, 8.77)	1.40 (0.12, 16.41)	0.40 (0.04, 3.84)	0.56 (0.04, 7.74)
PvCS	1.69 (0.33, 8.66)	1.09 (0.27, 4.34)	7.76 (0.53, 112.77)	4.49 (0.97, 20.86)	1.94 (0.28, 13.66)	2.18 (0.28, 17.08)	3.06 (0.38, 24.40)	6.11 (0.83, 44.98)	1.75 (0.31, 10.00)	2.46 (0.27, 21.95)
R0.6C-AIOH	0.77 (0.08, 7.61)	0.50 (0.06, 4.13)	3.56 (0.16, 80.30)	2.06 (0.22, 18.88)	0.89 (0.07, 11.08)	1.00 (0.07, 13.54)	1.40 (0.10, 19.25)	2.80 (0.22, 36.11)	0.80 (0.08, 8.53)	1.12 (0.07, 16.93)
R0.6C-AIOH/MM	0.62 (0.07, 5.84)	0.40 (0.05, 3.16)	2.84 (0.13, 62.28)	1.65 (0.19, 14.45)	0.71 (0.06, 8.53)	0.80 (0.06, 10.43)	1.12 (0.08, 14.84)	2.24 (0.18, 27.82)	0.64 (0.06, 6.55)	0.90 (0.06, 13.07)
RTS,S/AS01	0.98 (0.33, 2.89)	0.63 (0.34, 1.20)	4.51 (0.42, 48.72)	2.61 (1.03, 6.60)	1.13 (0.25, 5.16)	1.27 (0.24, 6.63)	1.78 (0.33, 9.51)	3.55 (0.73, 17.18)	1.01 (0.29, 3.52)	1.43 (0.23, 8.77)
RTS,S/AS02	0.93 (0.35, 2.50)	0.60 (0.38, 0.95)	4.27 (0.41, 44.30)	2.47 (1.09, 5.59)	1.07 (0.25, 4.58)	1.20 (0.24, 5.92)	1.68 (0.33, 8.50)	3.37 (0.74, 15.28)	0.96 (0.30, 3.07)	1.35 (0.23, 7.87)
SPf66	1.04 (0.28, 3.93)	0.67 (0.25, 1.83)	4.78 (0.39, 58.35)	2.77 (0.83, 9.24)	1.20 (0.22, 6.57)	1.35 (0.22, 8.34)	1.88 (0.30, 11.94)	3.77 (0.65, 21.77)	1.08 (0.25, 4.65)	1.51 (0.21, 10.88)
Treatment	PfCP	PfSPZ	ProC6C-AIOH	ProC6C-AIOH/MM	PvCS	R0.6C-AIOH	R0.6C-AIOH/MM	RTS,S/AS01	RTS,S/AS02	SPf66

BK-SE36	.	.	.	.	.	.	.	.	.	.
Control	0.86 (0.13, 5.77)	1.41 (0.62, 3.21)	0.40 (0.05, 3.16)	0.25 (0.03, 1.84)	1.09 (0.27, 4.34)	0.50 (0.06, 4.13)	0.40 (0.05, 3.16)	0.59 (0.29, 1.22)	0.61 (0.37, 0.98)	0.67 (0.25, 1.83)
EBA	.	.	.	.	.	.	.	.	.	.
FMP1/AS02	.	.	.	.	.	.	.	.	.	.
FMP2.1/AS02	.	.	.	.	.	.	.	.	.	.
GMZ2	.	.	.	.	.	.	.	.	.	.
JAIVAC	.	.	.	.	.	.	.	.	.	.
ME-TRAP	.	.	.	.	.	.	.	.	.	.
MSP3	.	.	.	.	.	.	.	.	.	.
PfAMA1	.	.	.	.	.	.	.	.	.	.
PfCP	PfCP	.	.	.	.	.	.	.	.	.
PfSPZ	1.65 (0.21, 13.13)	PfSPZ	.	.	.	.	.	.	.	.
ProC6C-AIOH	0.47 (0.03, 7.76)	0.28 (0.03, 2.62)	ProC6C-AIOH	0.63 (0.12, 3.36)	.	1.25 (0.20, 7.71)	1.00 (0.17, 5.84)	.	.	.
ProC6C-AIOH/MM	0.29 (0.02, 4.61)	0.18 (0.02, 1.53)	0.63 (0.12, 3.36)	ProC6C-AIOH/MM	.	2.00 (0.35, 11.37)	1.60 (0.30, 8.60)	.	.	.
PvCS	1.27 (0.12, 13.40)	0.77 (0.16, 3.85)	2.73 (0.23, 32.75)	4.37 (0.39, 49.41)	PvCS	.	.	.	.	.
R0.6C-AIOH	0.58 (0.03, 10.04)	0.35 (0.04, 3.41)	1.25 (0.20, 7.71)	2.00 (0.35, 11.37)	0.46 (0.04, 5.71)	R0.6C-AIOH	0.80 (0.13, 4.93)	.	.	.
R0.6C-AIOH/MM	0.47 (0.03, 7.76)	0.28 (0.03, 2.62)	1.00 (0.17, 5.84)	1.60 (0.30, 8.60)	0.37 (0.03, 4.40)	0.80 (0.13, 4.93)	R0.6C-AIOH/MM	.	.	.
RTS,S/AS01	0.74 (0.10, 5.53)	0.45 (0.16, 1.27)	1.59 (0.18, 13.79)	2.54 (0.31, 20.61)	0.58 (0.13, 2.66)	1.27 (0.14, 11.52)	1.59 (0.18, 13.79)	RTS,S/AS01	0.84 (0.31, 2.27)	.
RTS,S/AS02	0.70 (0.10, 4.99)	0.43 (0.17, 1.09)	1.50 (0.18, 12.48)	2.40 (0.31, 18.64)	0.55 (0.13, 2.36)	1.20 (0.14, 10.44)	1.50 (0.18, 12.48)	0.95 (0.47, 1.89)	RTS,S/AS02	.
SPf66	0.78 (0.09, 6.76)	0.48 (0.13, 1.74)	1.68 (0.17, 16.70)	2.69 (0.29, 25.07)	0.62 (0.11, 3.39)	1.35 (0.13, 13.93)	1.68 (0.17, 16.70)	1.06 (0.32, 3.47)	1.12 (0.37, 3.37)	SPf66

Lampiran 10 Tabel perbandingan hasil luaran demam

Treatment	BK-SE36	Control	EBA	FMP1	FMP1/AS02	FMP2.1/AS02	JAIVAC	ME-TRAP	MSP3	PfAMA1	PfSPZ
BK-SE36	BK-SE36	1.67 (0.41, 6.76)	.	.	.	.	.	.	.	.	.
Control	1.67 (0.41, 6.76)	Control	1.22 (0.04, 37.69)	.	0.54 (0.20, 1.44)	0.42 (0.06, 2.79)	5.90 (0.15,228.65)	0.07 (0.00, 2.26)	1.51 (0.33, 7.02)	2.00 (0.10, 39.37)	1.57 (0.51, 4.84)
EBA	2.04 (0.05, 82.84)	1.22 (0.04, 37.69)	EBA	.	.	.	.	.	.	.	.
FMP1	0.58 (0.02, 20.00)	0.35 (0.01, 8.98)	0.28 (0.00, 32.19)	FMP1	.	.	.	.	.	.	.
FMP1/AS02	0.91 (0.17, 5.00)	0.54 (0.20, 1.44)	0.45 (0.01, 15.81)	1.57 (0.05, 47.03)	FMP1/AS02	.	.	.	.	.	.
FMP2.1/AS02	0.71 (0.07, 7.39)	0.42 (0.06, 2.79)	0.35 (0.01, 17.41)	1.22 (0.03, 52.59)	0.78 (0.09, 6.51)	FMP2.1/AS02	.	.	.	.	.
JAIVAC	9.87 (0.20, 494.76)	5.90 (0.15, 228.65)	4.84 (0.03, 729.72)	17.06 (0.13, 2281.96)	10.86 (0.25, 478.03)	13.99 (0.23, 857.50)	JAIVAC	.	.	.	.
ME-TRAP	0.12 (0.00, 4.98)	0.07 (0.00, 2.26)	0.06 (0.00, 7.72)	0.21 (0.00, 24.03)	0.14 (0.00, 4.77)	0.17 (0.00, 8.73)	0.01 (0.00, 1.87)	ME-TRAP	.	.	.
MSP3	2.53 (0.32, 20.15)	1.51 (0.33, 7.02)	1.24 (0.03, 53.27)	4.37 (0.12, 159.87)	2.78 (0.45, 17.16)	3.58 (0.31, 40.88)	0.26 (0.00, 13.52)	20.51 (0.48, 874.77)	MSP3	.	.
PfAMA1	3.35 (0.12, 89.86)	2.00 (0.10, 39.37)	1.64 (0.02, 154.53)	5.78 (0.07, 477.19)	3.68 (0.16, 84.62)	4.74 (0.14, 161.42)	0.34 (0.00, 37.89)	27.13 (0.29, 2540.45)	1.32 (0.05, 37.79)	PfAMA1	.
PfSPZ	2.62 (0.44, 15.77)	1.57 (0.51, 4.84)	1.29 (0.03, 47.65)	4.53 (0.14, 142.01)	2.88 (0.65, 12.80)	3.71 (0.41, 33.51)	0.27 (0.01, 12.19)	21.26 (0.58, 782.19)	1.04 (0.15, 6.96)	0.78 (0.03, 18.95)	PfSPZ
ProC6C-AIOH	1.67 (0.08, 33.51)	1.00 (0.07, 14.19)	0.82 (0.01, 62.78)	2.89 (0.04, 192.62)	1.84 (0.11, 31.06)	2.37 (0.09, 61.50)	0.17 (0.00, 15.52)	13.56 (0.18, 1031.84)	0.66 (0.03, 14.18)	0.50 (0.01, 27.01)	0.64 (0.04, 11.39)
ProC6C-AIOH/MM	3.35 (0.12, 90.91)	2.00 (0.10, 39.88)	1.64 (0.02, 155.84)	5.78 (0.07, 481.36)	3.68 (0.16, 85.67)	4.74 (0.14, 163.18)	0.34 (0.00, 38.20)	27.13 (0.29, 2562.02)	1.32 (0.05, 38.22)	1.00 (0.01, 68.25)	1.28 (0.05, 31.24)
PvCS	3.68 (0.26, 51.69)	2.20 (0.23, 20.74)	1.81 (0.03, 108.95)	6.36 (0.12, 331.49)	4.05 (0.35, 46.74)	5.21 (0.28, 97.91)	0.37 (0.01, 27.19)	29.84 (0.50, 1789.97)	1.46 (0.10, 22.06)	1.10 (0.03, 45.84)	1.40 (0.11, 17.28)
R0.6C-AIOH	3.35 (0.12, 90.91)	2.00 (0.10, 39.88)	1.64 (0.02, 155.84)	5.78 (0.07, 481.36)	3.68 (0.16, 85.67)	4.74 (0.14, 163.18)	0.34 (0.00, 38.20)	27.13 (0.29, 2562.02)	1.32 (0.05, 38.22)	1.00 (0.01, 68.25)	1.28 (0.05, 31.24)
R0.6C-AIOH/MM	3.35 (0.12, 90.91)	2.00 (0.10, 39.88)	1.64 (0.02, 155.84)	5.78 (0.07, 481.36)	3.68 (0.16, 85.67)	4.74 (0.14, 163.18)	0.34 (0.00, 38.20)	27.13 (0.29, 2562.02)	1.32 (0.05, 38.22)	1.00 (0.01, 68.25)	1.28 (0.05, 31.24)
RTS,S	0.58 (0.05, 6.33)	0.35 (0.05, 2.41)	0.28 (0.01, 14.65)	1.00 (0.07, 13.65)	0.64 (0.07, 5.59)	0.82 (0.05, 12.31)	0.06 (0.00, 3.68)	4.69 (0.09, 240.57)	0.23 (0.02, 2.72)	0.17 (0.00, 6.06)	0.22 (0.02, 2.08)
RTS,S-coad	0.52 (0.05, 5.65)	0.31 (0.04, 2.15)	0.25 (0.00, 13.08)	0.89 (0.04, 22.63)	0.57 (0.06, 4.99)	0.73 (0.05, 10.99)	0.05 (0.00, 3.29)	4.19 (0.08, 214.80)	0.20 (0.02, 2.43)	0.15 (0.00, 5.41)	0.20 (0.02, 1.86)
RTS,S-FMP1	0.46 (0.02, 13.80)	0.28 (0.01, 6.11)	0.23 (0.00, 23.08)	0.80 (0.07, 8.90)	0.51 (0.02, 13.07)	0.66 (0.02, 24.63)	0.05 (0.00, 5.64)	3.75 (0.04, 379.46)	0.18 (0.01, 5.79)	0.14 (0.00, 10.16)	0.18 (0.01, 4.76)
RTS,S/AS01	1.72 (0.35, 8.39)	1.03 (0.49, 2.17)	0.85 (0.03, 28.35)	2.98 (0.11, 84.08)	1.90 (0.56, 6.48)	2.44 (0.32, 18.61)	0.17 (0.00, 7.29)	13.98 (0.42, 465.33)	0.68 (0.12, 3.76)	0.52 (0.02, 11.12)	0.66 (0.17, 2.54)
RTS,S/AS02	0.93 (0.20, 4.39)	0.56 (0.28, 1.10)	0.46 (0.01, 15.07)	1.60 (0.06, 44.66)	1.02 (0.31, 3.36)	1.32 (0.18, 9.80)	0.09 (0.00, 3.88)	7.53 (0.23, 247.33)	0.37 (0.07, 1.97)	0.28 (0.01, 5.90)	0.35 (0.10, 1.32)
SPf66	1.08 (0.15, 7.79)	0.65 (0.16, 2.61)	0.53 (0.01, 21.58)	1.87 (0.05, 64.60)	1.19 (0.22, 6.53)	1.53 (0.15, 16.05)	0.11 (0.00, 5.49)	8.79 (0.22, 354.32)	0.43 (0.05, 3.41)	0.32 (0.01, 8.69)	0.41 (0.07, 2.48)

Treatment	ProC6C-AIOH	ProC6C-AIOH/MM	PvCS	R0.6C-AIOH	R0.6C-AIOH/MM	RTS,S	RTS,S-coad	RTS,S-FMP1	RTS,S/AS01	RTS,S/AS02	SPf66
BK-SE36	.	.	.	.	.	.	.	.	.	.	.
Control	1.00 (0.07, 14.19)	2.00 (0.10, 39.88)	2.20 (0.23, 20.74)	2.00 (0.10, 39.88)	2.00 (0.10, 39.88)	0.35 (0.05, 2.41)	0.31 (0.04, 2.15)	.	1.13 (0.51, 2.50)	0.51 (0.25, 1.05)	0.65 (0.16, 2.61)
EBA	.	.	.	.	.	.	.	.	.	.	.
FMP1	.	.	.	.	.	1.00 (0.07, 13.65)	.	0.80 (0.07, 8.90)	.	.	.
FMP1/AS02	.	.	.	.	.	.	.	.	.	.	.
FMP2.1/AS02	.	.	.	.	.	.	.	.	.	.	.
JAIVAC	.	.	.	.	.	.	.	.	.	.	.
ME-TRAP	.	.	.	.	.	.	.	.	.	.	.
MSP3	.	.	.	.	.	.	.	.	.	.	.
PfAMA1	.	.	.	.	.	.	.	.	.	.	.
PfSPZ	.	.	.	.	.	.	.	.	.	.	.
ProC6C-AIOH	ProC6C-AIOH	2.00 (0.10, 39.88)	.	2.00 (0.10, 39.88)	2.00 (0.10, 39.88)	.	.	.	.	.	.
ProC6C-AIOH/MM	2.00 (0.10, 39.88)	ProC6C-AIOH/MM	.	1.00 (0.04, 27.06)	1.00 (0.04, 27.06)	.	.	.	.	.	.
PvCS	2.20 (0.07, 70.98)	1.10 (0.03, 46.32)	PvCS	.	.	.	.	.	.	.	.
R0.6C-AIOH	2.00 (0.10, 39.88)	1.00 (0.04, 27.06)	0.91 (0.02, 38.28)	R0.6C-AIOH	1.00 (0.04, 27.06)	.	.	.	.	.	.
R0.6C-AIOH/MM	2.00 (0.10, 39.88)	1.00 (0.04, 27.06)	0.91 (0.02, 38.28)	1.00 (0.04, 27.06)	R0.6C-AIOH/MM	.	.	.	.	.	.
RTS,S	0.35 (0.01, 9.26)	0.17 (0.00, 6.13)	0.16 (0.01, 3.06)	0.17 (0.00, 6.13)	0.17 (0.00, 6.13)	RTS,S	0.89 (0.13, 5.98)	0.80 (0.07, 8.90)	.	.	.
RTS,S-coad	0.31 (0.01, 8.27)	0.15 (0.00, 5.47)	0.14 (0.01, 2.73)	0.15 (0.00, 5.47)	0.15 (0.00, 5.47)	0.89 (0.13, 5.98)	RTS,S-coad	.	.	.	.
RTS,S-FMP1	0.28 (0.00, 16.30)	0.14 (0.00, 10.25)	0.13 (0.00, 5.75)	0.14 (0.00, 10.25)	0.14 (0.00, 10.25)	0.80 (0.07, 8.90)	0.90 (0.04, 19.27)	RTS,S-FMP1	.	.	.
RTS,S/AS01	1.03 (0.07, 16.21)	0.52 (0.02, 11.26)	0.47 (0.04, 4.98)	0.52 (0.02, 11.26)	0.52 (0.02, 11.26)	2.98 (0.37, 23.84)	3.33 (0.42, 26.64)	3.72 (0.15, 89.83)	RTS,S/AS01	0.95 (0.21, 4.39)	.
RTS,S/AS02	0.56 (0.04, 8.58)	0.28 (0.01, 5.98)	0.25 (0.02, 2.63)	0.28 (0.01, 5.98)	0.28 (0.01, 5.98)	1.60 (0.21, 12.56)	1.80 (0.23, 14.03)	2.01 (0.08, 47.68)	0.54 (0.22, 1.35)	RTS,S/AS02	.
SPf66	0.65 (0.03, 12.96)	0.32 (0.01, 8.79)	0.29 (0.02, 4.13)	0.32 (0.01, 8.79)	0.32 (0.01, 8.79)	1.87 (0.17, 20.42)	2.09 (0.19, 22.82)	2.34 (0.08, 69.66)	0.63 (0.13, 3.05)	1.17 (0.25, 5.50)	SPf66

Catatan: Hasil perbandingan ditampilkan dalam bentuk nilai risiko relatif dengan interval kepercayaan 95% dalam tanda kurung. Perbandingan langsung ditampilkan di atas label intervensi dan perbandingan tidak langsung ditampilkan di bawah label intervensi. Pewarnaan dalam kotak menunjukkan penilaian risiko bias (hijau = *low*, kuning = *some concerns*, merah = *high*)

Lampiran 11 Tabel perbandingan hasil luaran efikasi

	Control	FMP2.1/AS02	R21/MM	RTS,S/AS01	RTS,S/AS02	SPf66
Control	Control	1.10 (0.79,1.55)	2.72 (2.03,3.65)	1.32 (1.11,1.57)	1.47 (1.05,2.06)	1.11 (0.92,1.33)
FMP2.1/AS02	1.10 (0.79,1.55)	FMP2.1/AS02	.	.	.	.
R21/MM	2.72 (2.03,3.65)	2.46 (1.57,3.86)	R21/MM	.	.	.
RTS,S/AS01	1.35 (1.14,1.60)	1.22 (0.83,1.78)	0.49 (0.35,0.69)	RTS,S/AS01	1.05 (0.64,1.74)	.
RTS,S/AS02	1.53 (1.11,2.12)	1.39 (0.87,2.21)	0.56 (0.36,0.87)	1.14 (0.81,1.61)	RTS,S/AS02	.
SPf66	1.11 (0.92,1.33)	1.00 (0.68,1.47)	0.41 (0.29,0.58)	0.82 (0.64,1.06)	0.72 (0.50,1.05)	SPf66

Catatan: Hasil perbandingan ditampilkan dalam bentuk nilai risiko relatif dengan interval kepercayaan 95% dalam tanda kurung. Perbandingan langsung ditampilkan di atas label intervensi dan perbandingan tidak langsung ditampilkan di bawah label intervensi. Pewarnaan dalam kotak menunjukkan penilaian risiko bias (hijau = *low*, kuning = *some concerns*, merah = *high*)